- Home
- SWTX vs AVAL Comparison
SWTX vs AVAL Comparison
Compare SWTX & AVAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- AVAL
- Stock Information
- Founded
- SWTX 2017
- AVAL 1994
- Country
- SWTX United States
- AVAL Colombia
- Employees
- SWTX N/A
- AVAL N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- AVAL Commercial Banks
- Sector
- SWTX Health Care
- AVAL Finance
- Exchange
- SWTX Nasdaq
- AVAL Nasdaq
- Market Cap
- SWTX 3.5B
- AVAL 3.2B
- IPO Year
- SWTX 2019
- AVAL N/A
- Fundamental
- Price
- SWTX $46.26
- AVAL $2.83
- Analyst Decision
- SWTX Buy
- AVAL
- Analyst Count
- SWTX 7
- AVAL 0
- Target Price
- SWTX $56.86
- AVAL N/A
- AVG Volume (30 Days)
- SWTX 8.7M
- AVAL 123.5K
- Earning Date
- SWTX 05-20-2025
- AVAL 05-19-2025
- Dividend Yield
- SWTX N/A
- AVAL 3.83%
- EPS Growth
- SWTX N/A
- AVAL 195.30
- EPS
- SWTX N/A
- AVAL 0.01
- Revenue
- SWTX $191,589,000.00
- AVAL $2,951,771,633.00
- Revenue This Year
- SWTX $86.36
- AVAL $46.54
- Revenue Next Year
- SWTX $69.02
- AVAL $8.90
- P/E Ratio
- SWTX N/A
- AVAL $11.12
- Revenue Growth
- SWTX 3417.33
- AVAL 14.20
- 52 Week Low
- SWTX $28.21
- AVAL $1.94
- 52 Week High
- SWTX $62.00
- AVAL $3.32
- Technical
- Relative Strength Index (RSI)
- SWTX 58.93
- AVAL 58.46
- Support Level
- SWTX $46.10
- AVAL $2.66
- Resistance Level
- SWTX $46.27
- AVAL $2.84
- Average True Range (ATR)
- SWTX 0.90
- AVAL 0.10
- MACD
- SWTX 0.58
- AVAL 0.02
- Stochastic Oscillator
- SWTX 99.46
- AVAL 71.18
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About AVAL Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)
Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its segments include: Banking Services segment comprises Banking Services, fund management and trust businesses, storage companies and entities that manage low-value payment systems. Merchant Banking segment comprises Financial Sector (trust and brokerage), Gas and Energy Sector (includes natural gas and energy transportation and distribution businesses), Infrastructure Sector (includes road infrastructure projects, construction services, and operation and maintenance), Hotel Sector (includes hospitality services), Agribusiness Sector (includes palm oil, rubber and rice businesses). Pension and Severance Fund Management" segment comprise administrator of pension and severance funds; and Holding segment.